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*To the Editor:*

Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by chromosomal aberrations and somatic mutations that identify biologically distinct subsets and guide risk stratification for therapy.[1](#ajh25146-bib-0001){ref-type="ref"} Treatment‐associated changes in clonal architecture are common in AML, with emergence or clearance of specific sub‐clones driving sensitivity and resistance to therapy. Therefore, the molecular characterization of emerging clones may facilitate the selection of optimal targeted therapies and rational combinations.

Venetoclax, a selective BCL‐2 inhibitor, induced a complete response or complete response with incomplete blood recovery (CR/CRi) in 6/32 (19%) patients with AML who either had relapsed/refractory disease or were medically unfit for intensive chemotherapy.[2](#ajh25146-bib-0002){ref-type="ref"} In this report, we present a comparison of genetic biomarkers observed in pre‐ and post‐treatment specimens from 29 of the 32 patients enrolled on this phase II study. Measurable reduction in bone marrow (BM) blast counts was observed in 15/29 (52%) of the patients, including CR/CRi in 6, a ≥50% reduction in BM blasts in 5, and a more modest blast reduction of \<50% in 4 (Supporting Information Figure 1). The remaining patients (14/29, 48%) had no blast reduction.

We investigated the presence of somatic mutations commonly associated with AML in baseline and end‐of‐treatment samples. DNA isolated from blood and bone marrow specimens was analyzed by next‐generation sequencing using the TruSight Myeloid panel (Illumina), the FoundationOne Heme panel (Foundation Medicine), or whole exome sequencing (MD Anderson Cancer Center, Khalifa Institute). Comparison of mutations at baseline and end of treatment is shown in Figure [1](#ajh25146-fig-0001){ref-type="fig"}A.

![Mutations affecting response to venetoclax in AML. **A**, Mutations observed pre‐therapy and end of treatment with single agent venetoclax therapy. Yellow indicates *IDH* or *SRSF2* mutations; orange indicates *ZRSR2* mutations; blue indicates *FLT3‐ITD* or *PTPN11* mutations; purple indicates newly detected *FLT3‐ITD* or *PTPN11* mutations; blank cells indicate specific mutation was not detected, ^†^Biological activity defined as any reduction in BM blast count while on venetoclax therapy; **B**, Time on study for patients with mutations associated with intrinsic sensitivity (pre‐therapy *IDH*/spliceosome mutants) and intrinsic resistance (pre‐therapy *FLT3‐ITD/PTPN11* mutants) to venetoclax; **C**, Time on study for patients with mutations associated with intrinsic sensitivity, intrinsic resistance, and acquisition of mutations associated with acquired resistance (*FLT3‐ITD/PTPN11* mutants) to venetoclax; **D**, Tumor growth inhibition by venetoclax plus quizartinib in mice xenografted with *FLT3‐ITD^+^* MV‐4--11 cells](AJH-93-E202-g001){#ajh25146-fig-0001}

At baseline, 10/29 (34%) patients had mutations in isocitrate dehydrogenase 1/2 (*IDH1/2*) genes. Of these, 7 (70%) had a reduction in BM blasts, including 3 CR/CRi. At baseline, 11/29 (38%) patients had spliceosome mutations in *SRSF2* or *ZRSR2.* Ten (88%) of these patients had a decrease in BM blasts, including 3 CR/CRi. Seven patients had both *IDH1/2* and spliceosome mutations with BM blast reductions observed in 6 (86%). In total, 11/14 (79%) patients with mutations in *IDH1/2* or *SRSF2/ZRSR2* had evidence of BM blast reduction, including 4 CR/CRi, implicating these as possible markers of sensitivity to venetoclax (Figure [1](#ajh25146-fig-0001){ref-type="fig"}A).

Among 14 patients who did not have a decrease in BM blasts on venetoclax treatment, 3 (21%) had FMS‐like tyrosine kinase‐3‐internal tandem duplication (*FLT3‐ITD*) and 4 (29%) had protein tyrosine phosphatase, non‐receptor type 11 (*PTPN11*) mutation at baseline, with 1 having both. Three patients had baseline mutations in both the *IDH*/spliceosome and *FLT3‐ITD/PTPN11* groups and these three were the only patients who harbored *IDH*/spliceosome mutations and did not have BM blast reductions on venetoclax. The median time on study was 106 days (range, 50--256) for the *IDH*/spliceosome^+^ (*n* = 11) and 25 days (range, 15--31) for *FLT3‐ITD/PTPN11* ^+^ patients (*n* = 6) (*P* = .0018, Wilcoxon) (Figure [1](#ajh25146-fig-0001){ref-type="fig"}B). These data suggest that *FLT3‐ITD* or *PTPN11* mutations in AML may produce intrinsic/primary resistance to venetoclax.

We also performed mutational analysis on matched end‐of‐treatment samples from 20 patients at the time of AML progression/therapy termination. The *IDH1/2*, *SRSF2/ZRSR2*, *FLT3‐ITD,* and *PTPN11* mutations identified prior to treatment were still present at the end of therapy in all patients. Notably, in 5 *IDH*/spliceosome^+^ patients that were negative for *FLT3‐ITD*/*PTPN11* mutations at baseline, *FLT3‐ITD* (*n* = 2), *PTPN11* (*n* = 1), or both (*n* = 2) mutations were now detected in the end‐of‐treatment samples. The median time on study for these five patients was 87 days (range, 50--107) as compared to 131 days (range, 83--256) for the six patients who had *IDH*/spliceosome mutations at baseline and did not acquire *FLT3* or *PTPN11* mutations (Figure [1](#ajh25146-fig-0001){ref-type="fig"}C). Furthermore, two patients in whom venetoclax initially induced BM blast reductions had both *FLT3‐ITD* and *PTPN11* mutations newly detectable at the end of treatment in different subclones, based on allele frequency.

Based on our sequencing findings, we assessed the combination of venetoclax with the small‐molecule FLT3 inhibitor quizartinib in the *FLT3‐ITD*+ mutant xenograft model MV‐4--11 (Supporting Information Methods). *In vitro*, the MV‐4--11 cells were sensitive to BCL‐2 inhibition by venetoclax.[3](#ajh25146-bib-0003){ref-type="ref"} However, similar to our clinical observations, venetoclax did not inhibit the growth of these tumors when implanted *in vivo.* Daily dosing of quizartinib induced tumor regressions in this model, although the tumors regrew following cessation of therapy. Strikingly, co‐treatment with venetoclax and quizartinib induced similar tumor regressions as quizartinib alone but with significantly increased durability, preventing tumor re‐emergence for up to 3 months post‐cessation of treatment (Figure [1](#ajh25146-fig-0001){ref-type="fig"}D). These data suggest that combining venetoclax with FLT3 inhibitors could be highly effective for the treatment of FLT3‐mutated AML and may also prevent the emergence of FLT3‐mutated, venetoclax‐resistant sub‐clones in patients who do not have an already detectable FLT3 mutation.

In summary, our data suggest that *SRSF2/ZRSR2* and *IDH1/2* mutations may predict sensitivity to venetoclax therapy in AML. Chan et al. previously demonstrated that *IDH1/2* mutations can sensitize leukemic cells to venetoclax.[4](#ajh25146-bib-0004){ref-type="ref"} However, of the 10 *IDH1/2*‐mutated AML samples assessed in this trial, 7 had co‐occurring spliceosome mutations, making it difficult to determine whether only one or both of these mutations together predict for venetoclax sensitivity. Recent findings suggest that *IDH2* and *SRSF2* mutations cooperate to induce a lethal transplantable myeloproliferative neoplasm.[5](#ajh25146-bib-0005){ref-type="ref"} Additionally, *SRSF2* mutation is known to induce alternative splicing of genes involved in the apoptotic pathway, a possible link to venetoclax sensitivity.[6](#ajh25146-bib-0006){ref-type="ref"} We note that *FLT3‐ITD* or *PTPN11* mutations may confer primary and secondary resistance to venetoclax. Consistent with this, previous studies have shown that *FLT3‐ITD* or *PTPN11* mutations can enhance the expression of anti‐apoptotic BCL‐2 relatives like BCL‐X~L~ and MCL‐1.[7](#ajh25146-bib-0007){ref-type="ref"}, [8](#ajh25146-bib-0008){ref-type="ref"} When combined with venetoclax, the FLT3 inhibitor quizartinib induced more durable responses in *FLT3‐ITD+* tumor‐bearing mice than either agent alone (Figure [1](#ajh25146-fig-0001){ref-type="fig"}D). Thus, simultaneous targeting of BCL‐2 and FLT3 may be one approach to overcome primary resistance and prevent emergence of secondary resistance to venetoclax therapy in AML patients.

CONFLICT OF INTEREST {#ajh25146-sec-0102}
====================

Vivian Ruvolo, Zixing Wang, and Ken Chen: nothing to disclose. Evelyn McKeegan was an employee of AbbVie, Inc. at the time of the study and may own stock. Marina Konopleva: consulted for and received research grants from AbbVie Inc. and Genentech. Naval Daver: received research grants from AbbVie Inc. and Genentech. Brenda Chyla, Kelly Doyle, Xin Huang, Andrew Souers, Joel Leverson, Jalaja Potluri, Erwin Boghaert, Anahita Bhathena, Relja Popovic: employees of AbbVie Inc. and may own stock.

Supporting information
======================

Additional Supporting Information may be found online in the supporting information tab for this article.

###### 

**Supporting information 1**

###### 

Click here for additional data file.

Venetoclax is being developed by AbbVie and Genentech. AbbVie and Genentech provided financial support for the study and participated in the design, study conduct, analysis, and interpretation of data as well as the writing, review and approval of this Correspondence. The authors thank the patients and their families, study coordinators, and support staff. Medical writing support was provided by Namrata Bhatnagar, Ph.D., an employee of AbbVie.
